Sanofi has chalked up another win in a clinical trial of its oral BTK inhibitor rilzabrutinib, setting up regulatory filings in its first indication – rare disorder immune thrombocytopenia (ITP) – later this year in the US and EU.
Copyright © 2024 | WordPress Theme by MH Themes